To the content
1 . 2020

The role of the state in the development of innovative drugs

Abstract

The article is devoted to the analysis of macro indicators of the pharmaceutical industry and government policy aimed at stimulating the development and introduction of new drugs (medicinal products) in Russia, USA, EU (UK), South Korea and China. The objectives and certain measures in this direction are described, namely: increase of state investments and private funds for investments in research and development (R&D) and support of new drugs production, their stimulation of registration and marketing, support when entering the markets, marketing development, training of qualified personnel for the pharmaceutical industry. It has been shown that state programs to support the innovative development of the pharmaceutical industry are being actively implemented not only in the countries that traditionally lead in this area (USA and EU), but also in South Korea and China. Based on the analysis of these programs, it is recommended for the Russian Federation: to increase state funding for R&D by minimum 8 times, to expand the market for medications by increasing the volume of state purchases of medications, as well as to develop an intergovernmental management system.

Keywords:pharmaceutical industry, new drugs, choice of priorities in drug development, state programs for innovative development of pharmaceutical industry

For citation: Ulumbekova G.E., Khudova I.Yu. The role of the state in the development of innovative drug. ORGZDRAV: novosti, mneniya, obuchenie. Vestnik VSHOUZ. 2020; 6 (1): 83-99. DOI: 10.24411/2411-8621-2020-11005 (in Russian)

References

1. Penicillin: an accidental discovery changed the course of medicine Penicillin was first discovered in 1928 and is now the most widely used antibiotic in the world [Electronic resource]. URL: https://www.healio.com/endocrinology/news/print/endocrine-today/%7B15afd2a1-2084-4ca6-a4e6-7185f5c4cfb0%7D/penicillin-an-accidental-discovery-changed-the-course-of-medicine. (date of access January 20, 2020)

2. Unal В., Critchley J.A., Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation. 2004; 109 (9): 1101-7.

3. Lok A., et al. Benefits of direct-acting antivirals for hepatitis C. Ann Intern Med. 2017; 167 (11): 812-3. DOI: 10.7326/M17-1876.

4. Di Felice E., Roncaglia F., Venturelli F., et al. The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study. BMC Cancer. 2018; 18: 1069. DOI: 10.1186/s12885-018-4984-3.

5. IQVIA Institute for Human Data Science. The Global Use of Medicine in 2019 and Outlook to 2023, Jan 2019 [Electronic resource]. URL: https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023. (date of access January 20, 2020)

6. OECD, Health at a Glance 2019 [Electronic resource]. URL: https://www.oecd-ilibrary.org/docserver/4dd50c09-en.pdf?expires=1579511734&id=id&accname=guest&checksum=E5A53AB89DA93221AD8A030581E1E181. (date of access January 20, 2020)

7. Ostwald D., Zubrzycki K., Knippel J. Measuring the Economic Footprint of the Pharmaceutical Industry - Feasibility Study [Electronic resource]. URL: www.wifor.de. (date of access January 20, 2020)

8. Germany's Top 10 Exports [Electronic resource]. URL: http://www.worldstopexports.com/germanys-top-10-exports/ (date of access January 20, 2020)

9. Schuhmacher A. The Future of Pharma R&D Pharma Focus Asia Issue [Electronic resource]. URL: https://www.pharmafocusasia.com/research-development/future-of-pharma-research-and-development (date of access January 20, 2020)

10. The development of the pharmacy network in the Soviet period [Electronic resource]. URL: https://lektsii.org/4-24737.html. (date of access January 20, 2020) (in Russian)

11. Order of the Ministry of Industry and Trade of the Russian Federation of October 23, 2009 No. 965 “On approval of the Development Strategy of the pharmaceutical industry of the Russian Federation for the period until 2020” [Electronic resource]. URL: https://base.garant.ru/4189282/ . (date of access January 20, 2020) (in Russian)

12. Tsyb S. Now we are at a point where we have something to offer not only the domestic but also the international health care market [Electronic resource]. URL: http://ktovmed-icine.ru/2019/1/sergey-cyb-seychas-my-nahodimsya-v-toy-tochke-kogda-nam-est-chto-predlozhit-ne-tolko-otechestven-nomu-no-i-mezhdunarodnomu-rynku-zdravoohraneniya.html. (date of access January 20, 2020) (in Russian)

13. Decree of the President of the Russian Federation of May 7, 2018 "On national goals and strategic objectives of the Russian Federation" [Electronic resource]. URL: http:// www.kremlin.ru/acts/bank/43027 (date of access January 20, 2020) (in Russian)

14. The Government of the Russian Federation. On amendments to the state program of the Russian Federation “Development of the pharmaceutical and medical industry” [Electronic resource]. URL: https://regulation.gov.ru/projects#npa=98567.09.01.2020 (date of access January 20, 2020) (in Russian)

15. OECD statistics [Electronic resource]. URL: https://stats.oecd.org/ (date of access January 20, 2020)

16. Drugs and Medicine Exports by Country. [Electronic resource]. URL: http://www.worldstopexports.com/drugs-medi-cine-exports-country/ (date of access January 20, 2020)

17. The Pharmaceutical Industry and Global Health. International Federation of Pharmaceutical Manufacturers & Associations [Electronic resource]. URL: https://www.ifpma.org/wp-content/uploads/2017/02/IFPMA-Facts-And-Figures-2017.pdf (date of access January 20, 2020)

18. Healthcare in Russia 2017. Rosstat 2001-2017. Federal State Statistics Service. 2018[Electronic resource]. URL: https://www.gks.ru/storage/mediabank/zdravpdf. (date of access January 20, 2020) (in Russian)

19. Advancing Health Through Innovation. 2018 New Drugs Therapy Approval [Electronic resource]. URL: https:// www.fda.gov/files/drugs/published/New-Drug-Therapy-Approvals-2018_3.pdf. (date of access January 20, 2020)

20. Annual Report 2018. The European Medicines Agency's contribution to science, medicines and health in 2018 [Electronic resource]. URL: https://www.ema.europa.eu/en/news/ema-annual-report-2018-published. (date of access January 20, 2020)

21. Pharma R&D Annual Review 2019 [Electronic resource]. URL: https://pharmaintelligence.informa.com/re-sources/product-content/pharma-rnd-annual-review-2019. (date of access January 20, 2020)

22. The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development. Analysis [Electronic resource]. URL: https://www.analysisgroup.com/globalassets/content/insights/publishing/the_biopharmaceutical_pipeline_re-port.pdf. (date of access January 20, 2020)

23. Seimetz D., Heller K., Richter J. Approval of first CAR-Ts: have we solved all hurdles for ATMPs. Cell Medicine. 2018; 11: 1-16. DOI: 10.1177/2155179018822781.

24. Cohen J. China CRISPR revolution. Science. 2019; 365: 420-1.

25. Elhassa G.O., Alfarouk K.O. Drug development: stages of drug development. J Pharmacovigilance. 2017; 3: 140-1. DOI: 10.4172/2329- 6887.1000e141.

26. DiMasi J.A., Grabowski H.G., Hansen R.W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016; 47: 20-33.

27. Galkina Cleary E., Beierlein J., Khanuja N., et al. Contribution of NIH funding to new drug approvals 20102016. Proc Natl Acad Sci USA. 2018; 115 (10): 2329-34.

28. Governments and philanthropists announce new funding for neglected tropical diseases [Electronic resource]. URL: https://www.who.int/neglected_diseases/news/gov-ernments-and-philanthropists-announce-new-funding/en/ (date of access January 20, 2020)

29. Kim D., Kyle M. Korean Pharmaceutical Industry Policy: Lessons for Korea. Research Reports. Sejong, South Korea: Korea Institute for Health and Social Affairs, 2018.

30. Ekins S., Waller C, Bradley M., et al. Four disruptive strategies for removing drug discovery bottlenecks. Drug Discov Today. 2013; 18 (5-6): 265-71.

31. At Over $2 Million Zolgensma Is The World's Most Expensive Therapy, Yet Relatively Cost-Effective [Electronic resource]. URL: https://www.forbes.com/sites/joshuacohen/2019/06/05/at-over-2-million-zolgensma-is-the-worlds-most-expensive-therapy-yet-relatively-cost-effective/#e62cb1b45f5a (date of access January 20, 2020)

32. The Pharmaceutical Market in 2018. DSM group report [Electronic resource]. URL: https://dsm.ru/docs/ana-lytics/Annual_report_2018_DSM.pdf. (date of access January 20, 2020) (in Russian)

33. Science The Endless Frontier. A Report to the President by Vannevar Bush, Director of the Office of Scientific Research and Development. 1945 [Electronic resource]. URL: https://www.nsf.gov/od/lpa/nsf50/vbush1945.htm. (date of access January 20, 2020)

34. NIH Budget [Electronic resource]. URL: https:// www.hhs.gov/about/budget/fy2018/budget-in-brief/nih/index.html#budget . (date of access January 20, 2020)

35. National Center of Advancing Translational Sciences [Electronic resource]. URL: https://ncats.nih.gov/ (date of access January 20, 2020)

36. NIH, Office of Portfolio Management [Electronic resource]. URL: https://dpcpsi.nih.gov/opa. (date of access January 20, 2020)

37. Mowery D., Nelson D., Sampat B., et al. The growth of patenting and licensing by U.S. universities: an assessment of the effects of the Bayh-Dole act of 1980. Res Policy. 2001; 30: 99-119.

38. Mojica F., Rodriguez-Valera F. The discovery of CRISPR in archaea and bacteria. FEBS J. 2016; 283: 3162-9. DOI: 10.1111/febs.13766.

39. Jinek M., Chylinski K., Fonfara I., Doudna J., et al. A programmable dual RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012; 337 (6096): 816-21.

40. Le Cong, Ran F.A., Zhang F., et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339 (6121): 819-23. DOI: 10.1126/science.1231143.

41. Caribou Biosciences [Electronic resource]. URL: https://cariboubio.com/ (date of access January 20, 2020)

42. Editas Medicine [Electronic resource]. URL: https:// www.editasmedicine.com/ (date of access January 20, 2020)

43. FDA at Glance [Electronic resource]. URL: https:// www.fda.gov/about-fda/fda-basics/fact-sheet-fda-glance. (date of access January 20, 2020)

44. Regenerative Medicine Advanced Therapy Designation [Electronic resource]. URL: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation (date of access January 20, 2020)

45. Institute for Clinical and Economic Review [Electronic resource]. URL: https://icer-review.org/ (date of access January 20, 2020)

46. McKelvey M., Orsenigo L. Pharmaceuticals as a Sectoral Innovation System. In: ESSY Project (European Sectoral Systems of Innovation) [Electronic resource]. URL: http://plg-group.com/wp-content/uploads/2014/03/Phar-maceuticals-as-a-Sectoral-Innovation-System-McKelvey-M.pdf. (date of access January 20, 2020)

47. Innovative Medicine Initiative [Electronic resource]. URL: https://www.imi.europa.eu/ (date of access January 20, 2020)

48. Bernhard Z. Regional biotechnology - the EU biocluster study. J Commercial Biotechnol. 2011; 17: 209-17. DOI: 10.1057/jcb.2011.13.

49. Stevenage Bioscience Catalyst [Electronic resource]. URL: https://www.stevenagecatalyst.com/ (date of access January 20, 2020)

50. 2018 Directory of Korean Pharmaceutical Industry [Electronic resource]. URL: http://www.kpbma.or.kr/attach/KPBMA_Directory_2018.pdf (date of access January 20, 2020)

51. Kwon H., Yang B., Godman B. Key Components of increased drug expenditure in South Korea: implications for the future. Value Health Reg Issues. 2015; 6: 14-21. URL: http://dx.doi.org/10.1016/j.vhri.2015.01.004.

52. Chung H., Eum S., Lee C. Firm growth and R&D in the Korean pharmaceutical industry. Sustainability. 2019; 11: 2865. DOI: 10.3390/su11102865.

53. Rymzo B., et al. The modern merits of South Korea's biopharmaceutical industry. Int J Drug Dev Res. 2016; 8: 1-6.

54. The Right Place for Clinical Trials in Asia Start with Korea. Korea National Enterprise for Clinical Trials [Electronic resource]. URL: http://kcc.konect.or.kr/jsp/popup/file/Start%20with%20Korea_20160609.pdf (date of access January 20, 2020)

55. Ding J., Xue Y., Liang H., et al. From imitation to innovation: a study of China's drug R&D and relevant national policies. J Technol Manag Innovat. 2016; 6 (2): 1-13. URL: https://doi.org/10.4067/S0718-27242011000200001.

56. Atkinson R. China's Biopharmaceutical Strategy: Challenge or Complement to U.S. Industry Competitiveness? Information Technology and Innovation Foundation [Electronic resource]. URL: https://itif.org/publications/2019/08/12/chinas-biopharmaceutical-strategy-challenge-or-complement-us-industry (date of access January 20, 2020)

57. China Pharmaceutical Guide [Electronic resource]. URL: pharmachinaonline.com (date of access January 20, 2020)

58. Ni J., et al. Obstacles and opportunities in Chinese pharmaceutical innovation. Globalization Health. 2017; 13: 21. DOI: 10.1186/s12992-017-0244-6.

59. Ulumbekova G.E. Public Health Care of the Russian Federation. What needs to be done. Status and recommendations: 2019-2024. 3rd ed. Moscow: GEOTAR-Media, 2019: 202. (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Guzel E. Ulumbekova
MD, MBA from Harvard University (Boston, USA), Head of the Graduate School of Healthcare Organization and Management (VSHOUZ)

Journals of «GEOTAR-Media»